Table 1.

Immune cell markers in patients with solid tumors and their correlation with improved response to checkpoint inhibitor or TKI therapy

TumorTherapyImmune cell markers associated with improved response to therapy
mRCC (72)Atezolizumab
  • Increased baseline effector T-cell to regulatory T-cell gene expression ratio

mRCC (73)Nivolumab
  • Low baseline inflammatory index defined as platelets Ă— neutrophils/lymphocytes

mRCC (22)Atezolizumab + Bevacizumab
  • High effector T-cell signature gene expression

mRCC (74)Sunitinib
  • High tumor score for T-cell gene expression signatures (including CD8+ T cell, Th1 cell, Th2 cell, Treg cell, and stromal cell)

mRCC (22)Sunitinib
  • High expression of angiogenesis gene signature

mUC (75)Nivolumab
  • High CD8 expression

  • High CD8 combined with low epithelial–mesenchymal transition-associated gene expression

mUC (64)Cabozantinib
  • Low levels of Tregs at baseline

  • Changes in Treg PD-1 expression

  • Abbreviations: Th, T helper cell; Treg, regulatory T cell.